Table 3.
Clinical-pathological characteristics of the study participants who received T-DM1 in second-line after a trastuzumab-based first-line (N = 194) and after a pertuzumab-trastuzumab-based first-line (N = 177)
| Characteristics | First-line trastuzumab/ Second-line T-DM1 [N (%)] |
First-line pertuzumab-trastuzumab/Second-line T-DM1 [N (%)] | p-value |
|---|---|---|---|
| Progesterone Receptor | 0.83 | ||
| Positive | 91 (46.9%) | 85 (48.0%) | |
| Negative | 103 (53.1%) | 92 (52.0)% | |
| Estrogen Receptor | 0.46 | ||
| Positive | 132 (68%) | 114 (64.4%) | |
| Negative | 62 (32%) | 63 (35.6%) | |
| Ki-67% | 0.05 | ||
| ≤ 20 | 45 (25.6%) | 26 (16.6%) | |
| > 20 | 131 (74.4%) | 131 (83.4%) | |
| Immunohistochemical Subtype | 0.57 | ||
| TP | 87 (44.8%) | 81 (45.8%) | |
| ER or PgR positive | 45 (23.2%) | 33 (18.6%) | |
| ER and PgR negative | 62 (32.0%) | 63 (35.6%) | |
| Metastatic at Diagnosis | 0.05 | ||
| No | 147 (75.8%) | 117 (66.1%) | |
| Yes | 47 (24.2%) | 60 (33.9%) | |
| Number of Metastatic Sites | 0.14 | ||
| 1 | 142 (73.2%) | 117 (66.1%) | |
| > 1 | 52 (26.8%) | 60 (33.9%) | |
| Neo−/adjuvant treatment * | 0.38 | ||
| Yes | 128 (66.0%) | 109 (61.6%) | |
| No | 66 (34.0%) | 68 (38.4%) | |
| Neo−/adjuvant trastuzumab * | 0.48 | ||
| Yes | 76 (39.2%) | 63 (35.6%) | |
| No | 118 (60.8%) | 76 (39.2%) | |
| Visceral Metastatic Site(s) | 0.11 | ||
| Yes | 133 (68.9%) | 135 (76.3%) | |
| No | 60 (31.1%) | 42 (23.7%) | |
| Disease Free Intervala | 0.10 | ||
| < 3 years | 66 (46.8%) | 47 (41.2%) | |
| ≥ 3 years | 75 (53.2%) | 67 (58.8%) | |
aFor patients with early disease at diagnosis
Abbreviations: N Number; TP Triple positive; ER Estrogen receptor; PgR Progesterone receptor